- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01510665
Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals
Magnesium Supplementation in the Second Trimester of Pregnancy for Overweight Individuals
This is a prospective, randomized, placebo controlled study with three parallel arms examining the effects of magnesium supplementation in the second trimester of pregnancy.
Recent research has shown that supplemental magnesium can have beneficial effects, especially in overweight individuals. Not only do many people have a magnesium deficient diet, there is also evidence that magnesium can improve blood sugar levels. Due to the growing concern of obesity with pregnancy and its associated complications, such as diabetes and abnormal fetal growth, magnesium therapy could have novel and beneficial effects on pregnancy outcomes.
In this study, 60 overweight and obese pregnant patients in their first trimester will be enrolled and randomized. The first group (A) will receive oral magnesium citrate (300mg elemental Magnesium), group B will receive dietary counseling about following a magnesium rich diet from a nutritionist, and group C will receive a placebo (control). Blood and urine specimens will be collected at three time points during the pregnancy to analyze changes in levels of metabolic markers, inflammatory markers, and protein expression profiles. Fetal and maternal complications of pregnancy will be noted, including maternal weight gain. At delivery, patients will have a placental cord blood specimen and placental biopsy collected for gene expression patterns and further analysis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Westwood, California, Forente stater, 90095
- 200 Medical Plaza UCLA Ob/Gyn Clinic
-
Westwood, California, Forente stater, 90095
- West Medical UCLA Ob/Gyn Clinic
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Between 18 and 40 years of age
- Pregnant in the first trimester
- Able to give informed consent
- Planning to deliver at UCLA
- BMI greater than or equal to 25
Exclusion Criteria:
- On insulin therapy or other oral hypoglycemic agents
- Multiple gestation
- Baseline HgbA1C > 6.5%
- Prior history of clinically diagnosed T2D
- Multiple dietary restrictions/food allergies
- Heart, renal, or liver failure
- Clinical history of psychiatric illness or substance abuse
- Out of town travel planned at study visits
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Magnesium Supplement
Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
|
Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
|
Placebo komparator: Placebo
Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
|
Identical appearing placebo with inactive ingredients, two pills once daily.
|
Aktiv komparator: Diet
Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
|
Nutritionist counseling session and advice on following a magnesium rich diet
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in maternal biomarkers during pregnancy up to 28 weeks
Tidsramme: up to 28 weeks
|
Blood and urine markers of inflammatory and metabolic markers will be assessed during the pregnancy,comparing baseline values to second trimester values, which will be up to 28 weeks.
|
up to 28 weeks
|
Neonatal birth weight/height
Tidsramme: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization.
Neonatal weight and height at birth will be assessed.
|
Up to 10 months
|
Change in maternal biomarkers in pregnancy in the third trimester
Tidsramme: Up to 36 weeks
|
Blood and urine markers of inflammatory and metabolic markers will be assessed during the pregnancy,comparing baseline values to third trimester values, which will be up to 36 weeks.
|
Up to 36 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Neonatal outcomes
Tidsramme: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization. At delivery, neonatal characteristics will be assessed: Macrosomia, preterm birth, head circumference, and apgar score. |
Up to 10 months
|
Neonatal tertiary outcomes
Tidsramme: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization.
Cord blood and placenta will be collected at delivery, and we will examine endothelial progenitor cell presence in cord blood, PON expression in cord blood, and DNA expression from the placental tissue.
|
Up to 10 months
|
Pregnancy complications
Tidsramme: Up to 10 months
|
From date of randomization until the date of delivery of the neonate, up to a maximum of 10 months, pregnancy complications such as development of gestational diabetes, hypertension, proteinuria, shoulder dystocia, cesarean section, as well as amount of weight gain will be assessed from the chart.
|
Up to 10 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Simin Liu, MD, ScD, MS, MPH, University of California, Los Angeles
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Magnesium123
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Magnesium citrate
-
Sir Charles Gairdner HospitalUkjentKroniske nyresykdommer | Sluttstadium nyresykdom | Dialyserelaterte komplikasjoner
-
Zydus Therapeutics Inc.SuspendertDyslipidemierForente stater
-
Zydus Therapeutics Inc.FullførtIkke-alkoholisk SteatohepatittForente stater
-
Salem Anaesthesia Pain ClinicRekrutteringSteroid metabolismeforstyrrelseCanada
-
Sohag UniversityHar ikke rekruttert ennå
-
National Center for Complementary and Integrative...Fullført
-
National Heart, Lung, and Blood Institute (NHLBI)FullførtHjerteinfarkt | Myokardiskemi | Hjertesykdommer | Kardiovaskulære sykdommer | Koronar sykdom
-
Zydus Therapeutics Inc.RekrutteringPrimær biliær kolangittForente stater, Argentina, Island, Tyrkia
-
Avecho BiotechnologyHar ikke rekruttert ennå
-
Mayo ClinicRekrutteringBlærespasmerForente stater